Rising Tide Foundation for Clinical Cancer Research (RTFCCR)–MRA Team Science Award on Melanoma Early Detection, Diagnosis, and Risk Stratification
Funds collaborative research teams for translational and early clinical studies that advance early detection, diagnosis, and risk stratification of melanoma, with required patient partner involvement.
Funder: Melanoma Research Alliance
Due Dates (Anticipated): October 2026 (Letter of Intent) | February 2027 (Invited full proposal)
Funding Amounts: Up to $900,000 total over 3 years (direct costs only; no indirects); up to two awards expected.
Summary: Supports multidisciplinary, team-based research projects advancing early detection, diagnosis, and risk stratification of melanoma.
Key Information: Patient partner involvement is required throughout the project; eligibility and team composition rules are strict.
Description
This special Team Science Award, offered jointly by the Melanoma Research Alliance (MRA) and the Rising Tide Foundation for Clinical Cancer Research (RTFCCR), funds collaborative research teams to advance the early detection, diagnosis, and risk stratification of melanoma. Emphasizing translational and early clinical research, the award seeks projects with strong potential for near-term clinical impact, including clinical validation studies or pilot (phase I) clinical trials. Successful applications must demonstrate active patient partner involvement throughout the research lifecycle, from study design to dissemination.
